Biogen, Inc. has listed driving a potential return to growth in its biosimilars business as one of its key near-term operational priorities, after its biosimilars revenue decreased 5% year-on-year during the first quarter of 2022. Pricing pressure and negative currency impacts took their toll on the segment, as revenue decreased from $205m in Q1 2021 to $194m this year, with the company ultimately expecting a “slight” decline in full-year biosimilars revenue overall compared to 2021.
The firm currently has three biosimilars on the market: Imraldi (adalimumab), Flixabi (infliximab) and Benepali (etanercept), developed through the Samsung Bioepis Co., Ltd. former joint venture with Samsung BioLogics. Flixabi experienced the most substantial YoY hit overall, dropping 16
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?